Safety and early benefits of an injection plus radiation for cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 1 study tests whether KRC-01, given by injection into the tumor, is safe and tolerable when combined with standard chemoradiation for locally advanced cervical cancer. It also looks for early signs that the treatment can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign informed consent before any study steps
- Have cervical cancer in the uterus cervix that was confirmed by biopsy as squamous cell, adenocarcinoma, or adeno-squamous
- Have stage II or III cancer that has not spread to distant organs (no metastases)
- Have a measurable tumor larger than 5 cm that is reachable for injection and has not been previously irradiated
- Be able to start and complete radiation plus cisplatin treatment within about 8 weeks, with planned external-beam radiation (EBRT) and then brachytherapy (BT)
- Be physically able for treatment (ECOG 0 or 1) and able to avoid pregnancy during treatment and for 3 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a feasibility (“can it be done safely?”) approach that delivers radiation in a shorter schedule for some cervical cancer patients. It also uses weekly cisplatin chemotherapy and includes a radiation procedure called brachytherapy to improve treatment effectiveness.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This study tests a combination of two chemotherapy drugs (nab-paclitaxel and cisplatin) given alongside radiation therapy for people with locally advanced cervical cancer. The goal is to see if this combination is safe and effective in shrinking the cancer and improving outcomes.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This trial looks at whether adding chemotherapy after standard chemoradiation helps people with locally advanced cervical cancer. You may be eligible if your MRI after treatment still shows leftover tumor areas and your health and blood tests are within required limits.
This study tests whether combining immunotherapy with chemotherapy, followed by radiation plus immunotherapy, can work better than standard treatment for cervical cancer. It aims to help patients whose cancer has not spread yet.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.